Vaccine compositions and uses thereof
The present disclosure relates to nonstructural protein 1 (NS1) from flaviviruses and uses thereof. In particular, the present invention relates to diagnostic and therapeutic uses of NS1 to treat and prevent disease caused by flaviviruses.
1. A composition for inducing an immune response, comprising:
a) one or more peptides selected from the group consisting of SEQ ID NOs: 51-54 and peptides that are at least 80% identical to SEQ ID NOs: 51-54; and
b) an adjuvant that enhances the ability of said one or more peptides to induce an immune response.
2. The composition of claim 1 , wherein said peptides are at least 90% identical to SEQ ID NOs: 51-54.
3. The composition of claim 1 , wherein said peptides are at least 95% identical to SEQ ID NOs: 51-54.
4. The composition of claim 1 , wherein said adjuvant is selected from the group consisting of an insoluble suspension of acylated sugars, cationically or anionically derivatized polysaccharides, diphosphoryl lipid A, 3-O-deacylated variants of diphosporyl lipid A, QS7, QS17, QS21, unmethylated CpG dinucleotides, interleukin-2, interferon-γ, interleukin-4, macrophage colony stimulating factor, tumor necrosis factor, monophosphoryl lipid A, and OM-174.
5. A method of inducing an immune response in a subject, comprising: administering the composition of claim 1 to a subject.
6. A kit comprising the composition of claim 1 .
7. The kit of claim 6 , wherein said kit further comprises a device for administering said composition to a subject.
8. The kit of claim 7 , wherein said device is selected from the group consisting of a syringe, a needle, and an intranasal delivery device.